Gylden Pharma
Private Company
Funding information not available
Overview
Gylden Pharma, formerly known as Emergex, is a private biotechnology company advancing a novel platform of T cell-priming vaccines. Its technology combines immunoproteomics, a nanocluster delivery system, and a microneedle array patch to target conserved viral peptides, aiming for broad, variant-resistant, and durable immunity. The company's lead candidate for Betacoronaviruses has been selected for NIH/NIAID Project NextGen clinical trials, positioning it in the next-generation vaccine landscape against pandemic threats. With in-house GMP manufacturing and a clear focus on infectious diseases, Gylden is targeting some of the world's most pressing immunological challenges.
Technology Platform
Integrated platform combining immunoproteomics (MHC Class I ligandome library), an ultrasmall carbohydrate-passivated nanocluster delivery system for synthetic peptides, and an intradermal microneedle array patch (MAP) for administration. Designed to elicit broad, long-lasting T-cell immune responses.
Opportunities
Risk Factors
Competitive Landscape
Gylden competes in the next-generation vaccine space against large pharma (e.g., Moderna, Pfizer, GSK) and biotechs also pursuing universal flu and pan-coronavirus vaccines. Its primary differentiation is its focus on conserved T-cell epitopes via a synthetic peptide/nanocluster platform, contrasting with the dominant mRNA and viral vector platforms that primarily elicit antibody responses.